Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2012 Oct 13;19(1 0):S38–S43. doi: 10.1016/j.bbmt.2012.10.003

Figure 1. Cumulative incidences of relapse GVHD.

Figure 1

Cumulative-relapse incidence for patients with HL following RIC acute grade II–IV or extensive chronic GVHD (20·2% [95% CI 5·9–69·6%]) versus those with no GVHD or with only grade I acute or limited chronic GVHD (50·7% [35·4–72·4%]). Reprinted from The Lancet, 365, Peggs K.S., Hunter A., Chopra R., Parker A., Mahendra P., Milligan D., Craddock C., Pettengell R., Dogan A., Thomson K.J., Morris E.C., Hale G., Waldmann H., Goldstone A.H., Linch D.C., and Mackinnon S., Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation, 1934–1941, Copyright (2005), with permission from Elsevier.